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Abstract
Accumulating evidence has demonstrated that human cancers arise from various tissues of origin 
that initiate from cancer stem cells (CSCs) or cancer-initiating cells. The extrinsic and intrinsic 
apoptotic pathways are dysregulated in CSCs, and these cells play crucial roles in tumor initiation, 
progression, cell death resistance, chemo- and radiotherapy resistance, and tumor recurrence. 
Understanding CSC-specific signaling proteins and pathways is necessary to identify specific 
therapeutic targets that may lead to the development of more efficient therapies selectively 
targeting CSCs. Several signaling pathways—including the phosphatidylinositol 3-kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR), maternal embryonic leucine zipper kinase 
(MELK), NOTCH1, and Wnt/β-catenin—and expression of the CSC markers CD133, CD24, 
CD44, Oct4, Sox2, Nanog, and ALDH1A1 maintain CSC properties. Studying such pathways may 
help to understand CSC biology and lead to the development of potential therapeutic interventions 
to render CSCs more sensitive to cell death triggered by chemotherapy and radiation therapy. 
Moreover, recent demonstrations of dedifferentiation of differentiated cancer cells into CSC-like 
cells have created significant complexity in the CSCs hypothesis. Therefore, any successful 
therapeutic agent or combination of drugs for cancer therapy must eliminate not only CSCs but 
differentiated cancer cells and the entire bulk of tumor cells. This review article expands on the 
CSC hypothesis and paradigm with respect to major signaling pathways and effectors that regulate 
CSC apoptosis resistance. Moreover, selective CSC apoptotic modulators and their therapeutic 
potential for making tumors more responsive to therapy are discussed. The use of novel therapies, 
including small-molecule inhibitors of specific proteins in signaling pathways that regulate 
stemness, proliferation and migration of CSCs, immunotherapy, and noncoding microRNAs may 
provide better means of treating CSCs.
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I. INTRODUCTION
The major limitation of cancer chemotherapy has proven to be apoptosis refractoriness and 
drug resistance, whether intrinsic to the malignancy due to resistance to cell death (colon 
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cancer, pancreatic cancer, glioblastoma, and prostate cancer are typically refractory to cancer 
chemotherapy) or acquired by the malignancy after transient disease remission (e.g., after 
breast cancer chemotherapy). Numerous mechanisms have been found to cause 
chemotherapeutic resistance in cancer cells.1–5 Understanding the mechanisms of resistance 
will assist in the design of more effective strategies to overcome it in cancer cells and 
tumors. Defects in apoptotic signaling and redundant survival mechanisms in malignant cells 
contribute to drug resistance in various cancer types.5–9 Therefore, strategies to lower the 
thresholds for triggering apoptosis in CSCs and various cancers may lead to new and more 
effective therapeutic regimens.5–9
Drug resistance can emerge due to a host of environmental factors as well as genetic or 
epigenetic alterations in cancer cells.10–13 These factors are particularly important in the 
interconversion of CSCs to differentiated cells and vice versa,13 which make therapeutic 
approaches quite complicated. Evolutionary theory has contributed to our understanding of 
the dynamics of drug resistance mutations in a cancer cell population, the risk of resistance 
pre-existing the initiation of therapy, the drug cocktail composition necessary to prevent the 
emergence of resistance, and optimum drug administration schedules for patients at risk of 
evolving acquired resistance.14 Adding to the complexity of successful treatment of tumors 
is the recent demonstration of dedifferentiation of differentiated cancer cells into CSC-like 
cells due to epigenetic plasticity.13 This proves that any successful therapeutic agent or 
combination of drugs for cancer therapy must eradicate not only CSCs but the differentiated 
cancer cells and the entire bulk of tumor cells.
Several factors, including the tumor environment, pharmacodynamics, and intertumor and 
intratumor heterogeneities in individual patients, also contribute to unresponsiveness of 
cancer cells to therapies. Moreover, various genetic alterations that result in redundant and 
increased cytoprotective and survival pathways, as well as numerous defects in the apoptotic 
signaling machinery and epigenetic changes, contribute to highly aggressive tumors. The 
main cause of death in patients with incurable tumors is recurrence of the malignancy, which 
is attributed to treatment-resistant CSCs within the primary tumor and the tissues 
surrounding it. The concept of a subset of CSCs believed to play a significant role in tumor 
formation, metastasis, cancer recurrence, and resistance to anticancer therapies has gained 
significant traction. CSCs are a relatively rare cell population in a tumor and have been 
described by different molecular markers and cellular features in different types of cancers. 
Thorough and in-depth molecular characterization of the CSC population as well as 
delineation of the heterogeneity of these cells in many tumors will allow us to refine the 
targeted agents that force CSCs to apoptosis, thus enhancing the development of more 
effective treatments.
In this review article, signaling pathways that regulate the CSC survival, proliferation, and 
resistance to apoptosis and anticancer agents, and the potential of specific proteins in the 
apoptosis pathways for developing novel and effective inhibitors to eliminate CSCs, are 
discussed. There has been great interest in targeting CSCs for improved cancer treatment 
through triggering apoptosis, inhibiting metastasis, and overcoming drug resistance in the 
cells.13–16 Understanding and characterizing the molecular mechanisms that control 
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unresponsiveness of CSCs to various apoptotic stimuli will help in the design of more 
effective therapies against a variety of cancers and prevent tumor recurrence.
II. APOPTOSIS PATHWAYS
A. Mitochondrial Pathway
Apoptosis is one of the most crucial and well-studied mechanisms regulating tissue 
development and homeostasis through a complex and orderly network of molecules that 
mediate death and survival signals. This orderly and tightly regulated programmed cell death 
involves signal transduction pathways that induce cells to self-destruct during embryonic 
development or in response to radiation-induced DNA damage and anticancer drugs. 
Apoptosis signaling pathways prevent cancer development, but specific mutations in normal 
stem cells transform these cells to CSCs (Fig. 1) and enable them to escape apoptosis and 
lead to tumor formation. Two major pathways, the extrinsic or cell surface death receptors 
pathway, and the intrinsic or mitochondria-initiated pathway, control apoptosis (Fig. 2).17–19 
The extrinsic apoptotic program is initiated by the binding of membrane-bound death 
receptors (DRs) with their ligands—for example, Fas/Fas ligand interaction, tumor necrosis 
factor-α (TNF-α)/TNF receptor 1 (TNFR1), or TNF-related apoptosis-inducing ligand 
(TRAIL)/DR5 interaction and cell death (Fig. 2).
Ligand binding leads to aggregation of DRs and recruitment of the adaptor protein FADD, 
initiator pro-caspase-8, and pro-caspase-10 to form the DISC complex. Pro-caspase-8 or 
pro-caspase-10 is then converted to its active form, which further activates the effector 
caspases-3, -6, and -7. Active caspase-3 initiates the downstream caspase cascade leading to 
apoptosis. Active caspases-8 and -10 are known to cleave a proapoptotic Bcl-2 family 
member, Bid, and the truncated Bid induces mitochondrial cytochrome C release,19–22 
thereby linking the two pathways. After activation, both caspases-8 and -9 activate 
caspase-3, which in turn cleaves other caspases and many cellular proteins.19
B. Death Receptor Pathway
The death receptor (DR)-initiated pathway is suppressed by c-FLIP, which inhibits death-
inducing signaling (DISC) formation and activation of caspases- 8 and -10, and prevents 
downstream apoptotic signaling. The mitochondrial or intrinsic pathway is initiated by 
receptor-independent apoptotic stimuli (e.g., DNA damage, radiation, and chemotherapeutic 
agents), which trigger mitochondrial outer membrane permeabilization (MOMP) by 
activation of Bcl-2 homologous proapoptotic proteins (e.g., Bax, Bak, and Bad) and the 
Bcl-2 homology domain-3–(BH3-) only family of proteins including Bid, Bim, or 
PUMA.19–22 MOMP in turn causes inner membrane permeability, and the various anti- and 
pro-apoptotic members of the Bcl-2 family form an interactive network that finally regulates 
the release of apoptosis-triggering factors, including certain caspases, Smac/DIABLO, and 
others from the mitochondrial intramembrane space to the cytosol.19,23 Cytochrome C and 
dATP bind to apoptotic proteinase-activating factor-1 (Apaf-1); this complex, along with 
adenine nucleotides, promotes procaspase-9 autoactivation, which in turn activates 
caspases-2, -3, -6, -7, -8, and -10.
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III. CANCER STEM CELLS AND APOPTOSIS
A. Cancer Stem Cell Phenotype
CSCs have the capacity for self-renewal, have multilineage differentiation potential capable 
of generating differentiated progenitor cells, are responsible for tumor cell heterogeneity, 
and can recapitulate the initial tumor. Escape from the complex apoptosis machinery is 
essential for CSCs. CSCs may arise from normal stem cells or progenitor cells (Fig. 1) 
following transforming mutations and as a result of epigenetic plasticity as well as 
interconversion and dedifferentiation of non-CSCs to CSCs.23,24 Three important criteria 
define CSCs: (a) only a low number of cancer cells within a tumor are usually endowed with 
the ability to recapitulate the original tumor; (b) they are identified and characterized by 
immunopheno-typing and express distinctive surface markers and can be differentially 
separated from non-CSCs by fluorescent activated cell sorting (FACS) analysis and flow 
cytometry; and (c) the tumors generated from CSCs express the phenotypic heterogeneity of 
the parent tumor containing mixed populations of CSCs and non-CSCs.13,25,26
CSCs are resistant to apoptosis, anticancer drug treatment, and radiation therapy; 
overexpress ABC-family efflux multidrug transporters to detoxify or mediate the release of 
cytotoxic agents from the cells27; display overexpression of Chk1/2 DNA damage repair 
proteins28,29; show rapid response to DNA damage29,30; express up-regulation of 
antiapoptotic proteins; and are resistant to oxidative stress. All of these characteristics 
contribute to the development of therapeutic resistance. Moreover, CSCs have been found to 
have crucial roles in various cancers, including breast, brain, ovarian, prostate, pancreatic, 
hepatocellular, head and neck, and hematological malignancies. While the identification and 
characterization of CSCs have been very useful in understanding their role in tumor 
initiation, oncogenesis, and distant metastasis, therapeutic targeting of CSCs has met 
significant difficulties due to their heterogeneous nature, which enables them to escape the 
cellular mechanisms that regulate apoptosis.
B. Stem Cell Signaling Pathways
Accumulating evidence has demonstrated that various cancers are initiated from CSCs that 
are responsible for the patient’s resistance to therapies. 13,23,30–33 Moreover, due to the 
heterogeneity, high diversity, and plasticity of CSCs, developing therapeutics to target these 
cells will be challenging. Furthermore, experimental evidence suggests a possibility of non-
CSC reprogramming and conversion to CSCs13 (Fig. 1). Therefore, effective anticancer 
treatment must eliminate both CSCs and the entire bulk tumor population as well as prevent 
tumor dedifferentiation of non-CSCs to CSCs. Various signaling pathways, including 
activated PI3K/AKT/mTOR, maternal embryonic leucine zipper kinase (MELK), NOTCH1, 
and Wnt/β-catenin, regulate CSC survival and proliferation. 31–37 These pathways as well as 
expression of CSC markers including CD133, CD44, Oct4, Sox2, Nanog, and ALDH1A1 
maintain CSC properties.
Olmez et al.38 recently demonstrated the difficulty of dealing with CSCs by inducing 
dedifferentiation of patient-derived GBM cell lines into GSC-like cells (induced GBM stem 
cells, iGSCs) through the expression of Oct4, Sox2, and Nanog transcription factors. The 
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iGSCs formed neurospheres even in the absence of exogenous mitogens, were sensitive to 
the CSC inhibitor salinomycin, and exhibited resistance to temozolomide (TMZ) therapy. 
Moreover, NOTCH1 and Wnt/β-catenin signalings and expressions of CD133, CD44, and 
ALDH1A1 were induced in iGSCs. These results indicate that dedifferentiation of cancer 
cells to induced iCSCs causes complexity in treating malignant tumors and that any 
therapeutic intervention should be designed to eliminate GSCs as well as iGSCs that may 
result from treatment with a chemotherapeutic agent or radiation therapy.13
Recently, Iriondo et al.39 demonstrated that hypoxia-driven cancer stem–like cell enrichment 
results from a dedifferentiation process in breast cancer and that hypoxia-inducible factors 
(HIFs) are required for chemotherapy resistance of breast CSCs (BCSCs). The 
dedifferentiated cells upregulate multidrug resistance (MDR) genes via double-stranded 
RNA-dependent protein kinase– (PKR− like ER-resident kinase– (PERK-) nuclear factor 
erythroid 2-related factor 2 (Nrf2) (PERK-Nrf2) signaling, and suggest that targeting this 
pathway could sensitize drug-resistant cells to chemotherapy.40
We have demonstrated the indispensable role of DNA-dependent protein kinase (DNA-PK) 
in elevating the expression of P-glycoprotein (P-gp) and an siRNA or a small-molecule 
inhibitor of DNA-PK in preventing P-gp expression and drug resistance.41 Recently, the 
importance of the MDR1 gene and its product P-gp in GSC resistance to chemotherapy was 
reported by showing that, following prolonged chemotherapy, DNA-PK, P-gp, and CD133+ 
increase in recurrent GBM.42 Interestingly, doxorubicin markedly increased CD133, DNA-
PK, and MDR1 expression in GBM cells.42 These results show that CD133 and DNA-PK 
may increase MDR1 expression via the phosphatidylinositol- 3-kinase– (PI3K-) Akt 
signaling pathway. The PI3K downstream targets Akt and nuclear factor NF-κB, which 
interact with the MDR1 promoter, are also increased in these cells. Downregulation of 
CD133 and DNA-PK by small interfering RNA or inhibition of PI3K or Akt decreased Akt, 
NF-κB, and MDR1 expression. These data collectively demonstrate that targeting CD133 
and DNA-PK in combination with conventional chemotherapy may effectively eradicate 
GSCs and improve the prognosis for patients with GBM.
Another important protein, MELK, is a highly conserved serine/threonine kinase expressed 
in several human cancers and CSC populations.43 MELK plays critical roles in the formation 
and maintenance of CSCs, particularly in cell cycle control, cell proliferation, apoptosis, cell 
migration, cell renewal, embryogenesis, oncogenesis, and cancer treatment resistance and 
recurrence. MELK binds to and phosphorylates the oncogenic transcription factor FOXM1 
in GSCs. Recent results show that the catalytic subunit of Polycomb repressive complex 2, 
EZH2, is targeted by the MELK-FOXM1 complex, which in turn promotes GSC resistance 
to radiation.44 The highly potent MELK selective inhibitor OTS167 exhibits strong in vitro 
activity, conferring an IC50 of 0.41 nM, and in vivo effects in various human cancer 
xenograft models.45
The characteristics of CSCs that may help in the development of anti-CSC therapies include 
specific cell surface markers and particular networks of transcription factor (TF) signaling, 
aberrant signaling pathways, epigenetic alterations, reprogramming and plasticity, 
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interaction with the microenvironment and CSC niche, and use of particular metabolic 
pathways.
IV. MECHANISMS OF DEATH RESISTANCE IN CANCER STEM CELLS
A. Deficiencies in Apoptosis Pathways
Discovering distinct targets and delineating the molecular differences that prevent CSCs 
from proceeding to apoptosis hold enormous significance and promise for improving cancer 
therapy. Several mechanisms, including a deficiency in mitochondrial- mediated apoptosis,46 
downregulation of death receptors,47,48 upregulation of c-FLIP, overexpression of 
antiapoptotic Bcl-2 family members and inhibitors of apoptosis proteins (IAPs), over-
activation of ABC multidrug resistance transporters, and PI3K/AKT signaling contribute to 
enhanced resistance to cell death induction in CSCs in various cancers.31,32–35,48 These 
mechanisms are discussed in detail next.
B. Multidrug Resistance Transporters
Much evidence indicates that CSCs express ABCB1 (P-gp) and BRCP1/ABCB2. The ATP-
binding cassette transporter (ABC) family induces resistance to chemotherapy in several 
malignancies. 42,49–53 Recently, based on the expression of the ABC family member 
ABCB5, melanoma cancer stem cells (MCSCs) were identified and it was shown that 
ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling 
circuit.54 Wang et al.50 showed that Panc-1 pancreatic CSCs express high levels of CD133/
CD44/Oct4/Nestin compared to Panc-1 cells, are resistant to gemcitabine, and express high 
levels of P-gp as well as high anti-apoptotic proteins, but exhibit weak proliferative 
potential. It was recently shown that epigallocatechin gallate treatment significantly 
downregulates expression of P-gp, but not that of ABCG2 or O6-methylguanine-DNA 
methyltransferase, and simultaneously enhances sensitivity to TMZ in GSCs.55
C. The Crucial Role of the PI3K/AKT/mTOR Signaling Pathway in CSCs
This signaling pathway is a master regulator for malignancies and plays important roles in 
many cellular processes, including proliferation, apoptosis, differentiation, metabolism, and 
migration. Aberrant upregulated PI3K/AKT/mTOR signaling is implicated in tumor 
resistance to conventional therapies in many cancers. Recent studies have revealed that this 
signaling pathway also plays a major role in the CSC phenotype in several tumors. 56–59 The 
combination of the antidiabetic drug metformin, an inhibitor of PI3K/AKT/mTOR signaling, 
and the RAF inhibitor sorafenib effectively impact reduced TMZ resistance, significantly 
reduce GSC oxidative stress and efflux pump activity, and synergistically kill these cells52. 
Moreover, a recent report showed that BFZ-235, an inhibitor of PI3K/AKT/mTOR 
signaling, effectively suppresses the stemness of colon CSCs.50
D. Dysregulated Antiapoptotoic Proteins in CSCs
1. Bcl-2 Family of Proteins—Prominent hallmarks of cancer are apoptosis evasion and 
the ability to self-govern growth and proliferation. While several steps within the extrinsic 
and intrinsic apoptotic pathways are dysregulated in various cancers, the aberrant expression 
levels and ratios of apoptotic and antiapoptotic proteins and their contribution to survival 
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pathways in CSCs have not been characterized and delineated in detail. Bcl-2 family 
proteins consist of the antiapoptotic molecules Bcl-2, Bcl-xL, and Mcl-1, and the 
proapoptotic proteins Bax, Bak, Bid, Bim, Bik, Noxa, and Puma. High levels of 
antiapoptotic proteins, including Bcl-2 and Bcl-xL, have been described in GSCs.60 
Moreover, high levels of Bcl-2, Bcl-xL, and Mcl-1 are associated with GSC resistance.61–63 
The ratio of anti- to proapoptotic protein levels changes the balance of cell survival and 
controls the sensitivity of cancer cells to apoptotic stimuli.61 Furthermore, abnormal 
increases in the redux-sensing transcription factor Nrf2 promote CSC survival by elevating 
transcription of Bcl-2 and Bmi-1 genes (Bmi-1 is a member of Polycomb repressor complex 
1).64 Since the expression of these antiapoptotic proteins is critical for the survival of CSCs, 
significant efforts have been directed toward therapeutic interventions to eliminate CSCs 
using inhibitors of the Bcl-2 family of proteins.
2. TRADD Expression and NF-κB Activity—As shown in Fig. 2, tumor necrosis factor 
receptor 1– (TNFR1-) associated death domain protein (TRADD) is a crucial adaptor 
protein in TNFR1 signaling and has an essential role in NF-κB activation and survival 
signaling in CSCs.65 Downstream of DR4 and DR5 and the death-inducing signaling 
complex (DISC), TRAIL also promotes the formation of the intracellular Complex II, which 
is composed of FADD, TRADD, caspase-8, caspase-10, RIP1, TRAF2, and IKK-γ.66 NF-
κB is the transcription factor that promotes expression levels of various inflammatory 
cytokines and apoptosis inhibitory proteins. Cancer cells often contain constitutively 
activated NF-κB that provides them with increased survival and resistance to therapies. 
Increased expression of TRADD is sufficient to activate NF-κB in GSCs.67
In GBM, cytoplasmic TRADD expression is significantly associated with worse 
progression-free survival (PFS). Silencing TRADD in GSCs results in decreased NF-κB 
activity and decreased viability of these cells, suggesting that TRADD is required for 
maintenance of GBM stem cell populations. 67 Therefore, increased expression of 
cytoplasmic TRADD is both an important biomarker and a key driver of NF-κB activation in 
GBM, and supports an oncogenic role for TRADD in GBM. NF-κB activity supports the 
survival of CSCs in breast cancer, and inhibition of NF-κB by the small-molecule inhibitor 
parthenolide was shown to cause preferential induction of apoptosis in CSC and progenitor 
cells, but not in normal stem cells, in human prostate cancer populations.68 Similarly, NF-
κB activity is important for the survival of breast cancer CSCs, and these cells are 
preferentially sensitive to inhibitors of the NF-κB pathway by parthenolide, 
pyrrolidinedithiocarbamate, and diethyldithiocarbamate, indicating that high activity of NF-
κB plays a major role in the maintenance of CSCs.69
3. Inhibitor of Apoptosis Family Proteins in CSC—Increased expression of IAPs, a 
family of endogenous caspase inhibitors, helps cancer cells to evade apoptosis.70 The IAP 
family X-linked inhibitors of apoptosis include XIAP, cIAP1, cIAP2, survivin, ML-IAP, 
NAIP, and ILP-2.70–72 XIAP has the strongest antiapoptotic properties compared to other 
IAPs; it suppresses apoptosis signaling by binding to active caspase-3 and -7 and by 
preventing caspase- 9 activation.73 Interestingly, ZFP36, a mRNA binding protein that exerts 
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antitumor activity in GBM by triggering cell death, promotes depletion of cIAP2 and XIAP 
and leads to the association of RIP1 to caspase-8 and FADD in GSCs.74
IAPs function through interactions of their BIR (baculoviral IAP repeat) protein domains; 
these interactions are antagonized by Smac/Diablo, an inverse regulator for IAP family 
membersthat are involved in apoptosis. The Smac mimetics in combination with TRAIL 
induce the degradation of cIAP1 and XIAP and thus induce apoptosis in vitro and in vivo.75 
Therefore, they exert an antitumor effect on nasopharyngeal carcinoma CSCs. Combination 
treatment with TRAIL and other anticancer agents may be a promising strategy for the 
treatment of nasopharyngeal carcinoma. Survivin, another IAP family member, was shown 
to play a role in CD133+ cell chemoresistance to 5-fluorouracil (5-FU) through a 
mechanism related to survivin expression instead of MDR1, ABCG2, and AKT1 expression. 
Therefore, a survivin inhibitor may be a new targeted agent for effective treatment of 
CD133+ colon cancer.76
4. c-FLIP Overexpression in CSCs—Acutely induced chemosensitization of cancer 
cells occurs when a proapoptotic signaling program induced in neoplastic cells by a 
chemotherapy drug includes the disabling of a cytoprotective antiapoptotic response. This is 
shown by our discovery that acute exposure of human leukemia cells to Taxol triggers a 
proapoptotic program that entails coordinate caspase activation and downregulation of c-
FLIP.77 c-FLIP is a major antiapoptotic protein and an important cytokine and chemotherapy 
resistance factor that suppresses cytokine- and chemotherapy-induced apoptosis. It is 
expressed as long (c-FLIPL), short (c-FLIPS), and c-FLIPR splice variants in human cells. c-
FLIP binds to FADD and/or caspase-8 or -10 and TRAIL receptor 5 (DR5). This interaction 
in turn prevents deathDISC formation and subsequent activation of the caspase cascade.
c-FLIPL and c-FLIPS are also known to have multifunctional roles in various signaling 
pathways, and to activate and/or upregulate several cytoprotective and prosurvival signaling 
proteins that include Akt, ERK, and NF-κB. The possibility of developing novel modalities 
of cancer therapy that improve the efficacy and lessen the toxicity of cancer chemotherapy 
by targeting specific c-FLIP isoforms is very attractive.78
c-FLIP variants are involved in TRAIL and chemotherapeutic drug resistance in a wide 
range of human malignancies.78 Furthermore, a combined Taxol/c-FLIP targeted therapy 
may improve the therapeutic response to Taxol by enhancing downregulation of c-FLIP 
variants in concert with drug-induced apoptosis signaling.79 A similar observation was made 
when c-FLIP was silenced by its specific siRNA in breast CSCs, which rendered these cells 
sensitive to TRAIL-triggered apoptosis.
V. DRUGS KNOWN TO INCREASE APOPTOSIS IN CANCER STEM CELLS
A. Drugs Known to Downregulate c-FLIP and Increase DR5
Activation of CSC signaling pathways is central to resistance to apoptosis and cancer 
therapy. At present, conventional chemotherapy and radio-therapy are largely ineffective in 
depleting the CSC pool because of CSCs’ apoptosis resistance phenotype, which suggests 
the need for novel therapies that specifically target the sustaining CSCs for tumor 
Safa Page 8
Crit Rev Oncog. Author manuscript; available in PMC 2017 March 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
eradication and thus improve the poor prognosis of various cancers. Moreover, recent 
emerging reports have shown that some of the conventional chemotherapy agents trigger de-
differentiation of cancer cells to CSCs by triggering epigenetic alterations as well as 
propagating these cells in the recurrent tumor.13, 38,80–83 Hence, recurrent tumors display 
even more resistance to these drugs than the initial tumors, which means that the design of 
better treatment strategies that can eliminate or otherwise control CSC populations in tumors 
is necessary for their eradication. Some of the antiapoptotic drugs for targeting CSCs are 
listed in Fig. 2 and Fig. 3.
CSCs that contribute to cancer recurrence are frequently TRAIL resistant.79,84,85 Qi et al.84 
showed that CD133-positive brain cancer stem cells are resistant to TRAIL and express 
lower levels of caspase-8 protein and higher levels of Bcl-2 protein when compared with 
CD133-negative cells (p < 0.05). One mechanism that causes resistance to TRAIL and 
chemotherapeutics in a wide range of human malignancies is upregulation of c-FLIP. 
Substantial levels of c-FLIP are expressed in deadly human cancers such as ovarian, colon, 
glioblastoma, breast, colorectal, and prostate cancers, as well as multiple myeloma. c-FLIP 
is also implicated in TRAIL resistance owing to its overexpression in a substantial 
proportion of these malignancies77,78 as well as in CSCs.79 Furthermore, interference with 
c-FLIP expression sensitizes these tumor cells to TRAIL and drugs like Taxol and 
gemcitabine.86,87 In addition to its function as an apoptosis modulator, c-FLIP has cellular 
functions including increased cell proliferation and tumorigenesis.78 Silencing c-FLIP in 
CSCs results in sensitization of these cells to TRAIL85 and cisplatin.48
Monensin (a polyether ionophore antibiotic) and salinomycin (a compound structurally 
related to monensin) cause effective cell death in CSCs and are currently recognized as 
anticancer drug candidates. Monensin as well as other polyether antibiotics, including 
salinomycin, nigericin, narasin, and lasalocid A, enhance TRAIL-mediated apoptosis in 
glioma cells via ER stress, CHOP-mediated DR5 upregulation, and c-FLIP downregulation 
(see Fig 3 for this signaling pathway). Salinomycin has been shown to be highly effective for 
eradicating CSCs both in vitro and in vivo.88–90 It induces apoptosis via death receptor-5 
upregulation and decreased c-FLIP expression in cisplatin-resistant ovarian CSCs.91
Pancreatic ductal adenocarcinoma (PDA) is a very aggressive cancer that is lethal and has 
one of the worst outcomes among all cancers. PDA often recurs after initial treatment, 
resulting in patient death despite the use of any other treatment. Interestingly, in PDA 
patients DR5 is enriched in pancreatic CSCs compared with the bulk of tumor cells. Treating 
patient-derived PDA xenografts with gemcitabine, the first-line chemotherapeutic agent for 
PDA, initially reduces tumor size but does not affect CSC populations. 92 However, a 
combination of tigatuzumab, a fully humanized DR5 agonist monoclonal antibody, with 
gemcitabine is effective in killing CSCs and the bulk of tumor cells as well.92 This 
combination therapy has resulted in a remarkable reduction in pancreatic CSCs, later tumor 
remissions, and significant improvement in the time to tumor progression.92
It is believed that BCSCs mediate recurrence and drive the formation of metastatic tumors, 
the major cause of mortality in breast cancer patients. 93 Because of their heterogeneity, 
therapeutic targeting of BCSCs is hindered by their heterogeneous nature and resistance to 
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conventional therapeutics. Piggott et al.79 identified a therapeutic approach to selectively 
killing BCSCs, irrespective of their clinical subtype and heterogeneity. They found that c-
FLIP is upregulated in BCSCs from various breast cancer subtypes and that genetic 
suppression of c-FLIP by its siRNA partially sensitizes breast cancer cells to the anticancer 
agent TRAIL. Their results showed that in breast cancer cell lines, BCSCs are exquisitely 
sensitive to the derepression of this proapoptotic pathway due to loss of c-FLIP, which 
results in an 80% reduction in primary tumors, a 98% reduction in tumor metastases, and the 
loss of BCSC self-renewal. Taken together, the combination treatment of TRAIL or 
chemotherapy with agents that increase DR5, or inhibition of c-FLIP by pharmacological 
agents or genetic approaches, may offer an effective therapeutic strategy to eliminate these 
apoptosis-resistant CSCs.
B. Inhibitors of Bcl-2 Family Proteins
Activation of CSC signaling pathways is central to apoptosis and therapy resistance in 
various cancer types. ABT-263 (Navitoclax), a potent Bcl-2 family inhibitor, has been used 
against many tumor types.21,94 Pareja et al.95 recently reported a deregulated apoptotic 
pathway with elevated levels of Bcl-2 family proteins and increased activity of the PI3K 
signaling pathway in GBM and GSCs. These authors showed that ABT-263 and GDC-0941, 
a PI3K inhibitor, abrogate the ability of GSCs to form CSC neurospheres.95 Moreover, 
combining ABT-737 with the retinoid derivative fenretinide has been shown to target 
melanoma cancer stem cells by increasing caspase-dependent apoptosis.96 The antiapoptotic 
Bcl-2 family protein Mcl-1 is overexpressed in GBM and represents an important resistance 
factor to the BH-3 mimetic ABT-263. Additionally, GX15-070, a pan-Bcl-2 inhibitor that 
has shown promising antitumor activity in various malignancies, and combined treatment 
with ABT-263 and GX15-070 overcomes apoptotic resistance in established GBM cell lines, 
GBCs, primary cultures, and in vivo experiments97
ABT-263 has also been shown to inhibit cell proliferation and induce apoptosis in human 
esophageal cancer (EC) cells and their chemoresistant counterparts by targeting stemness 
pathways. 98 ABT-263 strongly suppresses CSCs, and the combination of ABT-263 and 5-
Fu significantly reduces tumor growth in vivo and suppresses the expression of stemness 
genes. Therefore, the combination of ABT-263 with cytotoxic anticancer therapeutics may 
be a useful strategy for apoptosis- resistant cancer cells.
Obatoclax, a pan-Bcl-2 inhibitor with promising efficacy, was recently shown by Berghauser 
et al.99 to overcome apoptosis resistance to the histone deacetylase inhibitors SAHA and 
LBH589, and to act as a radiosensitizer in patient-derived GSCs. Obatoclax had a synergistic 
effect with SAHA and LBH589 and sensitizes cells to HDACi/radiation therapy (RTx). It 
enhances caspase-3/7 and inhibites the Bcl-2 family proteins Bcl-xL and Mcl-1 in these 
CSCs. The authors found that the gene predictive for treatment response is the F-box/WD 
repeat-containing protein-7, which is related to Bcl-2 inhibition and HDACi sensitivity.99
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VI. ROLE OF MICRO RNA IN APOPTOSIS RESISTANCE AND ITS 
MODULATION
A decade ago, small non-protein-coding RNAs, a novel class of RNAs termed microRNAs 
(miRNAs), were found to be involved in carcinogenesis. These molecules function as 
endogenous suppressors of gene expression by binding to the 3’-untranslated region (UTR) 
of target mRNAs and trigger either cleavage of the mRNAs or induce translational 
repression in the cells. Functionally, two types of miRNAs have been described in cancer: 
tumor-suppressor and oncogenic.100–102 Ectopic expression of tumor-suppressor miRNAs 
and suppression of oncogenic miRNAs both generate antitumor effects by inhibiting cell 
proliferation and increasing cell death.103
miRNAs regulate the expression of various target genes and are dysregulated in CSCs, 
suggesting that they play a critical role in posttranscriptional gene regulation and function in 
various cellular processes in these cells.13,103 Various strategies, including miRNA mimics, 
miRNA antagonists, and nanodelivery, have been employed to suppress specific oncogenes 
or activate tumor suppressors.103 Accumulating evidence suggests that miRNAs play 
significant regulatory roles in CSC apoptotic and antiapoptotic pathways, proliferation, 
survival, differentiation, migration and invasion, drug resistance, and radiation 
resistance. 13,104–106 Moreover, they are innovative biomarkers and their expression patterns 
correlate with the developmental lineage and differentiation state of tumor cells.13,107–108 
Several deregulated miRNAs have been strongly implicated in regulating GSC self-renewal 
capacity, maintenance of stemness and plasticity, resistance to drugs and radiation therapy, 
and unresponsiveness to various apoptotic stimuli.106–108 miRNAs regulate several groups 
of apoptosis-related proteins; those targeting caspases, Bcl-2, Mcl-1, and c-FLIP are shown 
in Fig. 3. Several studies have found that by antagonizing Bcl-2, miR-15a, miR16-1, and 
miR-34 trigger apoptosis in various CSCs.109–112
miRNA-34 is a tumor suppressor of great interest and is downregulated in several types of 
cancer. 113,114 As shown by Rathod et al.,115 it is downregulated by targeting many 
oncogenes related to proliferation, apoptosis, and invasion. miRNA-34a is a potential 
prognostic marker for glioma as its expression negatively correlates with patient survival in 
Grade III and IV glial tumors.115 Expression of miR-34a is decreased in a graded manner in 
glioma and glioma stem cell lines as compared to normal brain tissues. Ectopic expression 
of miR-34a in glioma stem cells decreases their proliferative and migratory potential, 
induces cell cycle arrest, and causes apoptosis. Rathod et al. showed that the tumor 
suppressive function of miR-34a in GBM is mediated via Rictor, a component of the 
mTORC2 complex that causes pronounced effects on glioma malignancy through its effects 
on the AKT/mTOR pathway and Wnt signaling.
We initially showed a 21-bp deletion in the p53 tumor suppressor protein in one of the four 
conserved regions within its conformational domain, spanning codons 126–133 at exon 5 in 
multidrug resistant MCF-7/ADR cells.116 Park et al. recently demonstrated that miR-34a 
expression is downregulated in these cells compared with MCF7 cells.117 The authors 
hypothesized that this reduction is due to the p53 mutation in MCF7/ADR cells. They found 
that miR-34a is suppressed by treatment with p53 RNAi or the dominant-negative p53 
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mutant in MCF7 cells. Ectopic miR-34a expression reduces breast cancer stem cell 
properties and increases sensitivity to doxorubicin treatment by directly targeting NOTCH1. 
Furthermore, tumors from nude mice treated with miR-34a were shown to be significantly 
smaller compared with those of mice treated with control lentivirus. Therefore, increased 
expression of miR-34a by systemic delivery of a miR-34a mimic118 represents a novel 
therapeutic approach in chemoresistant breast cancer.
Recently, Floyd et al.119 showed that two candidate oncogenic microRNAs, miR-582-5p and 
miR-363, target caspase-3, caspase-9, and Bim in glioblastoma by binding to the UTR of the 
genes for these apoptotic targets and suppressing their ex pression (Fig. 3). The authors 
performed a phenotypic rescue using siRNA against the targets in the context of miR 
inhibition and showed that miR-363 and miR-582-5p can increase GBM survival.
VII. CONCLUSIONS AND FUTURE DIRECTIONS
It is believed that many tumors contain CSCs that initiate tumors, metastasize, and cause 
tumor recurrence. CSCs have the capacity to self-renew and recapitulate the entire 
heterogeneous tumor population. Much evidence suggests that CSCs are more resistant to 
therapies that target cell proliferation and apoptosis. They escape from conventional therapy, 
which leads to their decreased sensitivity to prior treatment and CSC enrichment. Similarly, 
dedifferentiation of non-CSCs to CSCs after drug treatment can lead to cancer relapse. 
Therefore, effective and successful anticancer therapy must eradicate not only CSCs but also 
the bulk of tumor cells within the tumor.
CSCs exhibit enhanced resistance to apoptosis due to defects in the death receptor pathway, 
an impaired mitochondrial-mediated pathway, and upregulation of antiapoptotic proteins. 
Since the apoptotic pathways are deregulated in cancer cells and CSCs, restoration or 
activation of cell death machinery by the targeting of particular proteins in these pathways is 
a logical and attractive strategy for cancer therapy. Downregulation of death receptors, 
upregulation of c-FLIP, overexpression of antiapoptotic Bcl-2 family members and IAPs, 
and activation of PI3K/AKT signaling contribute to enhanced resistance to cell death 
induction in CSCs from various cancers. Increased expression of death receptors by small 
chemical inhibitors and their activation by recombinant ligands and agonistic antibodies, 
inhibition of c-FLIP expression by compounds that enhance its degradation and/or inhibit its 
transcription, suppression of antiapoptotic proteins by small-molecule antagonists or 
interfering RNAs, inhibitionof multidrug transporters by their chemical inhibitors, and 
inhibition of the PI3K/AKT pathway have all been shown to trigger cell death in CSCs that 
are resistant to conventional therapy. Moreover, while dysregulated miRNAs have been 
implicated in CSC stemness and tumorigenesis, proapoptotic miRNAs and miR-mimics have 
been discovered that potentially can be used to target CSCs. Activation of apoptosis 
programs in CSCs appears to make these cells more sensitive to current anticancer regimens 
and novel drugs designed or identified to target CSCs, and may open new strategies for 
effective cancer treatment.
While significant progress has been made toward identification, characterization, and 
understanding of the signaling pathways of CSCs, future research should be conducted to (a) 
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determine the specific mechanisms of aberrant apoptotic programming that govern 
resistance to apoptosis in these cells; (b) explore whether the CSCs of each tumor type 
express various mechanisms of apoptosis resistance and whether different tumor types 
express common or different mechanisms of apoptotic resistance; (c) characterize what 
mechanisms of resistance to apoptosis evolve in CSCs treated with chemotherapy drugs and 
in therapy-induced dedifferentiation, resulting in the generation of CSCs that may behave 
differently than the initial CSCs within a tumor; (d) determine whether apoptosis-targeted 
therapies develop resistance in CSCs by mechanisms similar to those observed in 
conventional chemotherapy; and (e) develop strategies to combine conventional 
chemotherapy with CSC-targeted therapy to effectively trigger cell death in CSCs and 
eradicate them with acceptable toxicity to normal cells. Delineating these points may 
provide novel therapeutic approaches to triggering maximum cell death in the entire tumor 
cell population and better managing cancer therapy.
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ABBREVIATIONS
AIC apoptosis inhibitory complex
Apaf-1 apoptotic proteinase-activating factor-1
BH3 Bcl-2 homology domain-3
c-FLIP cellular FLICE (FADD-like IL-1β-converting enzyme inhibitory protein
CSCs cancer stem cells
DED death effector domain
DISC death-inducing signaling complex
DNA-PK DNA-dependent protein kinase
DR5 death receptor 5
ER endoplasmic reticulum
FADD Fas-associated via death domain
GBM glioblastoma multiforme
GSCs GBM stem cells
MELK maternal embryonic leucine-zipper kinase
Nrf2 nuclear factor erythroid 2-related factor 2
PDA pancreatic ductal adenocarcinoma
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PERK protein kinase RNA-like ER kinase
P-gp P-glycoprotein
PTP permeability transition pore
TNFR1 TNF receptor 1
TNF-α tumor necrosis factor-α
TRADD TNFR1-associated death domain protein
TRAIL TNF-related apoptosis- inducing ligand
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FIG. 1. 
Cancer stem cells (CSCs) and their implications for the development and progression of 
tumors. CSCs are generated from normal stem cells (NSCs) through tumorigenic 
transformation of several potential pathways, including Hh: hedgehog (Hh); epithelial–
mesenchymal transition (EMT); and mesenchymal–epithelial transition (MET). CSC and 
drug-induced CSCs (Di-CSCs) are enriched following conventional chemotherapy 
treatment.
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FIG. 2. 
Overview of the intrinsic and extrinsic apoptotic pathways, the TRADD/NF-κB survival 
pathway, and the growth factor (GF) receptors PI3K/AKT pro-survival signaling axis in 
CSCs. A logical strategy to target CSCs is to use inhibitors of the antiapoptotic and 
prosurvival proteins in these interconnected pathways as shown in this figure.
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FIG. 3. 
Antiapoptotic drugs and miRNAs for targeting CSCs. Some of the drugs and miRNAs 
known to decrease c-FLIP variants, increase DR5, and target Bcl-2 family members are 
shown.
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